valrubicinpembrolizumabnadofaragene firadenovecDurvalumaberdafitinib
…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…
7articles mentioning drugs
14drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Enfortumab vedotin ×
Enfortumab vedotin
This drug is selected. Its supporting articles are shown below.
Articles mentioning Enfortumab vedotin
7 articles · page 1 of 1enfortumab vedotinT-DxdCrown Bioscience
…BL/6-hNectin4, or WT mice. Tumor-bearing mice received T-Dxd or enfortumab vedotin monotherapy, or combination therapy with anti-PD1.Results The l…
Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates
Enfortumab vedotinEVmetastatic bladder canceradvanced or metastatic urothelial carcinoma
…Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) indicated for advanced…
Nivolumab-CTnivolumabgemcitabine-cisplatinpembrolizumabEV-Pembrolizumabenfortumab vedotingemcitabineurothelial carcinomaEuropean Medicines AgencyUC
…0 (95% CI, 0.45-0.81; p=0.0009) between EV-Pembrolizumab versus Nivolumab-CT. According to the ATE guide, these treatments presented a degre…
Enfortumab vedotinpembrolizumabEV–Pemla/mUCchemotherapyEV–Pem
…Objectives Enfortumab vedotin and pembrolizumab (EV–Pem) have recently been shown to improve …
Pembrolizumabenfortumab vedotinECOG Performance StatusDana-Farber Cancer Instituteurothelialbreast
…types were urothelial (n=307; 53.9%) and breast (n=125; 21.9%). Pembrolizumab (n=386; 67.7%) and enfortumab vedotin (n=291; 51.1%) were the m…
pembrolizumabEnfortumab vedotinaUCEV/PSignatera™urothelial cancer
…ve biomarker in patients with aUC commencing EV with or without pembrolizumab.Methods We conducted a multicenter, retrospective real-world an…